clinical trial · NCT07838155
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease
Eli Lilly and Company·phase4·not yet recruiting·n = 50
Alzheimer DiseaseDonanemab
brief summary
The main purpose of this study is to assess how well Donanemab is tolerated and what side effects may occur in Indian participants with early symptoms of Alzheimer's Disease (AD). For each participant, the study will last up to approximately 84 weeks and will include visits every 4 weeks.
started
Oct 1, 2026
primary completion
Jul 1, 2030
completion
Jul 1, 2030
last updated
Sep 24, 2026
official title
A Phase 4, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Tolerability of Donanemab in Indian Participants With Early Symptomatic Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol